$0.0174
-0.0226-56.5%
Last update: Nov 10, 7:59 PM
Karyopharm Therapeutics Inc
KPTINASDAQ
Karyopharm Therapeutics fell 99.3% from $5.46 to $0.04, behind the S&P 500's +9.8%. Its worst day was Nov 2 (−83.1%), and its low came Nov 9 at $0.04.
Nov 11, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-2.23 missed the $-2.10 estimate on $34.1M revenue (est. $33.2M); FY revenue guidance of $130.0M–$150.0M against the $145.3M consensus.
+21.3% · S&P 500 −1.5%
Story events cover the past 12 months · Times ET
EPS of $-1.24 beat the $-1.44 estimate on $35.1M revenue (est. $31.9M); FY revenue guidance of $130.0M–$150.0M against the $137.9M consensus.
+0.6% · S&P 500 +0.8%
Karyopharm Therapeutics closed at its highest level of the year, 95.4% above where the year started.
+6.2% · S&P 500 −0.3%
Karyopharm Therapeutics shares fell 72.6%, while the S&P 500 rose 0.7%.
−72.6% · S&P 500 +0.7%
EPS of $-2.32 missed the $-1.42 estimate on $33.4M revenue (est. $32.1M); FY revenue guidance of $130.0M–$150.0M against the $133.5M consensus.
−2.0% · S&P 500 +0.7%
Karyopharm Therapeutics shares fell 29.0%, while the S&P 500 rose 0.2%.
−29.0% · S&P 500 +0.2%
Karyopharm Therapeutics shares rose 28.7%, while the S&P 500 fell 1.2%.
+28.7% · S&P 500 −1.2%
Karyopharm Therapeutics shares fell 83.1%, while the S&P 500 fell 0.5%.
−83.1%, the year's worst day · S&P 500 −0.5%
Where it ended: a close of $0.04 on Nov 9, 2026. Up next: Q3 2026 earnings on Nov 24, 2026 (EPS est. $-1.26, revenue est. $33.2M).
Nothing in the past 12 months.
All KPTI dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for KPTI and SPY from Benzinga historical bars. Not investment advice.
